Stockwinners Market Radar for May 21, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Cathie Wood's ARK Investment bought 86.9K shares of Crispr Therapeutics today

18:40 EDT Point72 Asset Management reports 5.0% passive stake in Rapid7 - Point72 Asset Management disclosed a 5.0% stake in Rapid7, which represents over 3.1M shares. The filing does not allow for activism.

17:38 EDT Installed Building Products director Jackson sells 2,112 common shares - In a regulatory filing, Installed Building Products director Janet Jackson disclosed the sale of 2,112 common shares of the company on May 20 at a price of $211.6534 per share.

17:31 EDT AngioDynamics announces CE Mark approval in Europe for AlphaVac F1885 - AngioDynamics announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism. "The CE Mark represents a major step forward in enhancing patient care and safety for endovascular therapies in the EU, a market with a higher prevalence of PE when compared to the United States," said Laura Piccinini, AngioDynamics Senior Vice President/General Manager, Endovascular Therapies and International. "This designation allows us to broaden our reach and provide innovative solutions to more healthcare professionals treating patients diagnosed with PE - on an increasingly global scale."

17:26 EDT Broadway Financial appoints four senior officers to City First management team - Broadway Financial announced the addition of four experienced senior officers to the management team of City First Broadway. The Board of Directors of City First Broadway announced the appointment of Zack Ibrahim as Executive Vice President and CFO of the Company and the Bank. Ibrahim will also be the Principal Financial Officer and Principal Accounting Officer for Broadway. Elizabeth Sur has been appointed as Executive Vice President, General Counsel, and Chief Risk Officer of both Broadway and the Bank. In addition, City First Broadway appointed: Elise Adams as Chief Accounting Officer and Senior Vice President; and Gary Castellaw as Corporate Treasurer and Senior Vice President. These appointments were made, and became effective, as of May 15. All of these new executives will be based in Washington, D.C. As previously announced, Brenda J. Battey, Executive Vice President and CFO will retire by the end of the Q2. Prior to joining City First Broadway, Ibrahim was most recently Executive Director, Head of Corporate Finance at Texas Capital Bancshares where he led TCB's Expense Program designed to achieve targeted financial objectives by 2025, as well as projects to develop various strategic roadmaps for scaling the finance department in support of the TCB's growth strategy, including implementing the Oracle EPBS financial platform and enhancing TCB's pricing tool system for all lending, capital markets, and deposit pricing decisions. Prior to joining City First Broadway, Sur was most recently a Managing Director and Regulatory Intelligence executive at Wells Fargo Bank, responsible for identifying regulatory issues, developing sustainable solutions for those issues, and managing and reporting progress in resolving various regulatory matters.Adams was Chief Accounting Officer and Corporate Controller for EagleBank, where she was responsible for providing oversight of the accounting department and reporting functions, including management of the general ledger, accounts payable, reconciliations, and filings with the SEC and banking regulators. Castellaw was Treasurer and Controller for IDEMIA North America, Idemia America Corporation.

17:07 EDT M&T Bank raises quarterly dividend to $1.35 from $1.30 per share - M&T Bank announced that it has declared a quarterly cash dividend of $1.35 per share on its common stock. This represents an increase of 5c per share, or 4%, from the previous $1.30 per share dividend paid in the first quarter of 2024. The dividend will be payable June 28 to shareholders of record at the close of business on June 3.

17:03 EDT Eupraxia Pharmaceuticals announces new data from RESOLVE trial - Eupraxia Pharmaceuticals announced additional clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis, or EoE. The company intends to continue to periodically disclose additional data from the trial. The results announced from the first and second cohorts of the RESOLVE trial, using Eupraxia's DiffuSphere technology for EoE, are derived from lower doses of four to eight 1 mg injections of EP-104GI administered to a portion of each patient's lower esophagus. With ongoing dose escalation, there were only mild to moderate treatment-emergent adverse events, not likely related to EP-104GI. First and second cohorts maintaining signs of potential efficacy, showing improvements in symptom outcomes to 24 weeks. Reductions in Peak Eosinophil Counts, or PEC, and Eosinophilic Esophagitis Histology Scoring System, or EoEHSS, scores, representing severity and extent of disease, have been observed in all second cohort patients at 12 weeks. Data suggest the potential to extend periods between intra-esophageal injections with further extensions possible at higher doses. The company previously announced data from the trial on February 5. The data release announced adds the objective EoEHSS results and the patient symptom scores at 24 weeks. The third cohort of the RESOLVE trial has been fully dosed at five times greater than that of the first cohort, with eight 2.5 mg injections. This dosing pattern offers a higher local dose and a broader spread of drug in the esophagus. Improvement in symptom outcomes in all three patients from the third cohort, with mean improvement to symptom scores persisting out to week 12. Reductions in PEC and EoEHSS scores, representing severity and extent of disease, have been observed in the two evaluable patients from the third cohort at 12 weeks. One of the three patients in the cohort was determined not to have eosinophils after enrollment in the trial.

16:57 EDT Lululemon announces updated and more integrated organizational structure - Lululemon it is implementing an updated and more integrated organizational structure, in conjunction with the departure of Sun Choe, Chief Product Officer, who has resigned and will leave the company later this month to pursue another opportunity. The strategic organizational changes are intended to support the company's near- and long-term growth plans, accelerate product innovation, and further enable its go-to-market strategies. The company does not intend to replace the role of Chief Product Officer. Effective immediately, Jonathan Cheung, Global Creative Director, will report to CEO Calvin McDonald and will drive the product design and innovation roadmap, continuing to oversee Design, Innovation, and Product Development. Cheung has a successful track record with more than 30 years of experience in senior creative leadership roles at global brands. The company will also create a new team comprised of leaders from its Merchandising and Brand functions to scale its global and regional go-to-market strategies. Nikki Neuburger will become Chief Brand & Product Activation Officer, overseeing Merchandising, Footwear, and Product Operations, in addition to her current responsibilities leading Brand. Elizabeth Binder, Chief Merchandising Officer, will report to Neuburger.

16:52 EDT TransAlta announces Horizon Hill project achieves commercial operation - TransAlta (TAV) announced that the 200 MW Horizon Hill Wind Project, located in Logan County, Oklahoma, has achieved commercial operation. The facility is fully contracted to Meta Platforms (META), which is receiving both clean electricity and environmental attributes from the new facility.

16:48 EDT Nanobiotix provides update on NBTXR3 collaboration - Nanobiotix (NBTX) announced updates to its corporate strategy in view of progress in the company's collaboration for the co-development and global commercialization of lead therapeutic candidate NBTXR3. Nanobiotix is developing three nanoparticle-based therapy platforms in sequence. The first therapeutic candidate from the first platform, radioenhancer NBTXR3, is being developed and potentially commercialized in collaboration with NBTXR3 global licensee Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company. Nanobiotix plans to leverage the sustainable revenue it expects to come from the development and commercialization of NBTXR3 to further advance development of the two other platforms described in the conclusion of this announcement. In preparation for potential regulatory submission in the event of positive trial results, Nanobiotix and Janssen aligned at the collaboration's Joint Strategy Committee, or JSC, to transfer the global sponsorship of the Phase 3 pivotal head and neck cancer trial. Nanobiotix will continue to support Janssen in execution of NANORAY-312 during and after the sponsorship transfer is complete. Study operations will remain ongoing during the transfer. Following discussions that began at the end of 2023, and in view of the intended transfer of the sponsorship, the JSC recently aligned to a protocol amendment that would remove the planned futility analysis in light of robust, positive final data from the expansion part of Study 102, a Phase 1 study evaluating NBTXR3 in a similar population. Given that the Study 102 results provided satisfactory support for the NANORAY-312 trial design, the futility analysis was deemed unnecessary. This amendment is subject to review and approval by health authorities in all countries where NANORAY-312 is operational as well as by the sites participating in the study. To date, the amendment has been accepted by health authorities in several major regions in the study. Additionally, Nanobiotix and Janssen have agreed to a change in approach to the planned interim analysis such that interim data will analyzed and reported after both the requisite number of events have been observed and the last patient has been recruited in 1H2026, rather than immediately after the requisite number of events as originally planned. This revised approach helps to ensure that potentially positive trial results do not influence recruitment prior to completion of the study. As such, Nanobiotix now expects the interim analysis to be reported after the last patient is recruited in 1H2026.

16:38 EDT Cazoo plans voluntary liquidation - In a regulatory filing, the director of Cazoo, Cazoo Holdings Limited, and Cazoo Properties Limited appointed David Soden and Matthew Mawhinney of Teneo Financial Advisory Limited as Joint Administrators. Concurrently, the directors of Cazoo Group Ltd, the parent company of the companies which is listed on the New York Stock Exchange and based in the Cayman Islands, have begun steps to place Cazoo Group Ltd into voluntary liquidation. Notices of intention to appoint administrators were filed with the English High Court in respect of certain of the material subsidiaries of Cazoo that are incorporated in England. The company also disclosed that if its operating subsidiaries file for administration, it would need to consider the best options for the company at such time, and that the options may include filing for administration or winding up of the company. On May 21, each of Cazoo Holdings Limited, Cazoo Ltd, and Cazoo Properties Limited filed for administration in the United Kingdom. On May 21, Matthew Mawhinney and David Soden of Teneo Financial Advisory were appointed as joint administrators to each of Cazoo Holdings Limited, Cazoo Ltd, and Cazoo Properties Limited. Following their appointment, the Joint Administrators will manage the affairs, business and property of the Administration Companies. As part of the administration process, the Joint Administrators will continue to pursue sale transactions in respect of remaining assets of the Administration Companies, including the marketplace business and remaining customer collection centers, where they are in active dialogue with a number of parties interested in the marketplace business. Throughout 2023 and 2024, the Company's management and Board have been reviewing the strategic options available to the Company to satisfy its liquidity needs. In December 2023, the Company completed a series of restructuring transactions with its debt and equity holders, aimed at improving the Company's capital structure and reducing the Company's debt (the "Transactions"). Following the Transactions, the Company engaged with financial advisors with the intention of conserving cash and pursuing its strategic options, including engaging in an M&A process and realigning its business model. On March 6, 2024, we announced that we were pivoting the business to a marketplace model. On May 1, the company announced that Cazoo Ltd had successfully sold substantially all of its inventory, paid off its stocking loans and reduced employee numbers. As of May 21, the assets of certain vehicle repair centers and customer collection centers, as well as the wholesale division, have been sold. In each case a number of employees were transferred to the buyers. Together with other initiatives, the transition has reduced the cash burn of the company and its consolidated subsidiaries, resulting in a cash position in excess of GBP 98M at May 13 compared to GBP 113M at December 31, 2023. Despite the transition to optimize returns to creditors the Administrations mark the appropriate next step in the restructuring of the business. As noted above, the Joint Administrators for the Administration Companies will continue discussions with new and existing parties interested in the marketplace business, with a view to concluding a sale over the coming weeks. Notwithstanding the company's pivot to a marketplace model and the various asset disposals, Cazoo Group Ltd still would need to raise additional capital in the future in order to continue as a going concern in the medium- to long-term. In light of the foregoing, and the fact that the Administrative Companies, our material subsidiaries, have filed for administration, the board of directors of the company determined that it is in the best interests of the company and its stakeholders to commence the winding up of the Company. The Board plans to hold an Extraordinary General Meeting of Shareholders on June 6 to seek shareholder approval of the winding up of the company and will file proxy materials relating to the EGM with the Securities and Exchange Commission. If the shareholders approve the winding up, liquidators will be appointed, and they will liquidate any remaining assets and satisfy, or make reasonable provisions for, the company's remaining obligations. The board does not presently expect that there will be any remaining proceeds for our shareholders. On May 16, pursuant to that certain Indenture, dated as of December 6, 2023, Cazoo notified the trustee that the company did not make the required interest payments of approximately $5.3M that were due on May 15, 2024 and the company did not deliver its audited financial statements to the trustee as required under the Indenture. Under the Indenture, non-payment of the interest due resulted in a Default and the company has a 30-day grace period to make the Interest Payment before such non-payment constitutes an Event of Default. In addition, failure to deliver the audited financial statements constituted a Default under the Indenture and the company has a 60-day grace period after it receives written notice from the trustee or by holders of at least 25% in aggregate principal amount of the Senior Secured Notes then outstanding to deliver the audited financial statements before such non-delivery constitutes an Event of Default. Upon an Event of Default in relation to the two Defaults described above, the trustee or the holders of at least 25% in of the Senior Secured Notes then outstanding may declare the Senior Secured Notes to be due and payable immediately. The filing for Administration by the Administration Companies constitutes an Event of Default under the Indenture.

16:35 EDT Toll Brothers sees FY24 deliveries 10,400 to 10,800 units - Sees FY24 Average Delivered Price per Home $960,000 - $970,000.

16:32 EDT Toll Brothers reports Q2 net signed contract value up 29% at $2.94B - Reports Q2: Net signed contract value was $2.94 billion, up 29% compared to FY 2023's second quarter; contracted homes were 3,041, up 30%. Backlog value was $7.38 billion at second quarter end, down 12% compared to FY 2023's second quarter; homes in backlog were 7,093, down 6%. Home sales gross margin was 25.8%, compared to FY 2023's second quarter home sales gross margin of 26.4%.

16:29 EDT ShockWave Medical says HSR Act waiting period expired on May 20 - In a regulatory filing, Shockwave Medical stated: "As previously announced, on April 4, 2024, Shockwave Medical entered into an Agreement and Plan of Merger with Johnson & Johnson, a New Jersey corporation, and Sweep Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson & Johnson, providing for the merger of Merger Sub with and into Shockwave, with Shockwave surviving the Merger as a wholly owned subsidiary of Johnson & Johnson. The closing of the Merger is conditioned upon, among other things, the expiration or termination of the waiting period applicable to the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Shockwave and Johnson & Johnson each made the necessary filings under the HSR Act with the Antitrust Division of the U.S. Department of Justice and the U.S. Federal Trade Commission on April 18, 2024. The required waiting period under the HSR Act with respect to the Merger expired at 11:59 p.m., Eastern Time on May 20, 2024. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the Merger." The company notes that the closing of the merger remains subject to the satisfaction or waiver of other customary closing conditions and as previously announced, Shockwave has scheduled the special meeting of stockholders for May 29 to vote on adoption of the merger agreement.

16:18 EDT Rezolute announces RZ402 trial meets both primary endpoints - Rezolute announced topline results from the Phase 2 clinical study of RZ402 in patients with DME who are naive to or have received limited anti-vascular growth factor, or anti-VEGF, injections. 94 participants were enrolled in the U.S. multi-center, randomized, double-masked, placebo-controlled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period. RZ402 met both primary endpoints of change in macular edema, or CST, and a good safety profile. CST improved significantly at all RZ402 dose levels compared to placebo. Continued downward trajectory in CST over course of study and at end of treatment. No significant difference between RZ402 dose levels, though response was largest at the 200 mg dose. Sub-analysis by DME severity indicates an improvement of approximately 75 microns at the 200 mg dose. CST declined in most patients who received the 200 mg dose of RZ402, including clinically significant improvements from baseline in more than 20% of participants, compared to none in placebo, with high rates of worsening. RZ402 was safe and well-tolerated. Adverse events, or AEs, were generally mild and rates were comparable to placebo. Three participants experienced serious AEs which were all judged by the Investigator as unrelated to study drug. No ocular adverse effects that are typically seen with intravitreal injections. Electrocardiograms, or ECGs, vitals, and safety labs were unremarkable. Target concentrations were exceeded at all three dose levels and continue to support once daily oral dosing. In terms of secondary endpoints, no significant improvements in BCVA compared to placebo . In-line with expectations for a study of this duration. Observed improvements in CST would predict visual improvements in a longer duration study. Five RZ402 treated participants at 200 mg experienced a 1-step improvement in Diabetic Retinopathy Severity Score compared to one participant in placebo. The Company plans to present these data and further findings at an upcoming medical conference.

16:15 EDT ViaSat expects to grow revenue and Adjusted EBITDA again in FY26 - The company said, "A preliminary view of FY26 indicates we expect to grow revenue and Adjusted EBITDA again in FY26 relative to FY2025 as a majority of our $3.3B assets under construction go into commercial service. Capital expenditures for FY26 are expected to continue to decline to a range of $1.1B-$1.2B. Consistent to prior guidance, we expect an inflection to positive free cash flow by the end of Q1 FY26 driven by double-digit operating cash flow growth and accelerating declines in capital expenditures as we work toward more normalized capital expenditure levels in line with satellites going into commercial service."

16:09 EDT Tantech Holdings receives Nasdaq notice of non-compliance - Tantech Holdings announced that it received a notice of non-compliance from Nasdaq Stock Market on May 20, 2024 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended December 31, 2023, the company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the SEC. This notice has no immediate effect on the listing or trading of the company's common shares on the Nasdaq. Under Nasdaq's listing rules, the company has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the company can be granted up to 180 calendar days from the Form 20-F's due date, or until November 11, 2024, to regain compliance.

16:08 EDT Infinera receives delinquency notification from Nasdaq - Infinera announced that it received an expected delinquency notification letter from Nasdaq on May 15. The notice indicated that Infinera remains in noncompliance with Nasdaq Listing Rule 5250 as a result of its failure to timely file its quarterly report on Form 10-Q for the quarter ended March 30, as described more fully in Infinera's Form 12b-25 Notification of Late Filing filed with the SEC on May 10. The Listing Rule requires listed companies to timely file all required periodic financial reports with the SEC. On May 14, Infinera announced its preliminary financial results for the quarter ended March 30.

16:06 EDT WSFS Financial names David Burg CFO, Arthur Bacci COO - WSFS Financial announced that David Burg will join the Company as Executive Vice President, Chief Financial Officer on August 15, 2024. In this role, Burg will be responsible for leading the Company's financial operations and strategy, including Financial Planning and Analysis, Accounting and Financial Reporting, Treasury, and Investor Relations. Prior to joining WSFS, Burg held several senior leadership positions during his nearly 17 years at Citigroup. Most recently, he was the Head of Strategy and Execution for Legacy Franchises. From 2021 to 2023, he was Chief Financial Officer for the entire Latin America region. Burg also served as the Chief Financial Officer of Citigroup's Treasury & Trade Solutions from 2017 to 2021. In these roles, he was responsible for financial reporting, financial planning and analysis, treasury management and strategy. Earlier in his career, Burg was a Managing Director in the Corporate Mergers & Acquisitions Group at Citigroup. He also held roles at McKinsey & Company and General Electric. WSFS also announced that Arthur J. Bacci will assume the role of Executive Vice President, Chief Operating Officer, coincidental with the appointment of Burg as CFO. Bacci joined WSFS in April 2018 as Executive Vice President, Chief Wealth Officer. In addition to serving as Chief Wealth Officer, he has held the role of interim Chief Financial Officer since August 2023. In his new role as Chief Operating Officer, Bacci will have oversight responsibilities for the Commercial, Wealth, Consumer and Cash Connect lines of business, as well as Technology, Operations, Customer Experience, Marketing and Communications. As part of WSFS' on-going succession planning, in conjunction with Bacci's appointment to Chief Operating Officer, Jamie P. Hopkins will be elevated to the role of Executive Vice President, Chief Wealth Officer. Hopkins joined WSFS in October 2023 as Senior Vice President and Director of Private Wealth Management. As Chief Wealth Officer, Hopkins will lead WSFS' Wealth Management segment which includes Bryn Mawr Trust, Bryn Mawr Capital Management, LLC, The Bryn Mawr Trust Company of Delaware, Powdermill Financial Solutions, WSFS Institutional Services, WSFS Wealth Investments, and WSFS Private Banking.

16:01 EDT Autodesk acquires Wonder Dynamics for undisclosed amount - Autodesk announced it has acquired Wonder Dynamics, makers of Wonder Studio which is a cloud-based 3D animation and VFX solution that combines artificial intelligence, or AI, with established tools. Wonder Studio is highly compatible with other popular 3D tools including Autodesk Maya, helping artists more easily animate, light, and compose 3D characters within live-action scenes. Autodesk's acquisition of Wonder Dynamics will give more creators the ability to add 3D animated characters to their projects and stories while minimizing the learning curve and automating typically complex and time-consuming processes. Terms of the deal were not disclosed. Wonder Dynamics makes the visual effects process more accessible and affordable by developing AI and machine learning tools that allow filmmakers to produce VFX and CGI elements faster and at a significantly lower price point.

15:40 EDT Oddity says 'deep misinformation' in short report 'cannot go unanswered' - Oddity issued a press release that states in part: "While ODDITY doesn't engage with self-interested short sellers and hostile interests, the level of deep misinformation in this report cannot go unanswered. ODDITY fundamentally rejects the short seller report. The allegations contained in the report by NINGI Research are based on demonstrable factual inaccuracies, incorrect assumptions, and unfounded and malicious speculation. The short seller report was published without any involvement by ODDITY... The main allegation in the report that the Israeli brick-and-mortar business is a significant portion of ODDITY's revenue and EBITDA is a complete falsehood. ODDITY's parent company is an Israeli entity, a fact that could have led to the fundamental misunderstanding in the report regarding the source of our group revenue. The brick-and-mortar business in Israel (43 retail stores and 6 beauty schools) represents an immaterial part of our business, accounting for less than 5% of ODDITY's Net Revenue and less than 5% of ODDITY's EBITDA in both FY2023 and Q1 2024. The Israeli business operations have always been reflected in our financial disclosures. All of ODDITY's revenue outside of Israel is exclusively from online sales. All of ODDITY's Israeli subsidiaries are fully audited by Ernst & Young, our auditors on record, and the financial statements are filed with the Israeli authorities. Their results are consolidated with the group, as required, hence there are no standalone reports. The overwhelming majority of the 'hundreds of lawsuits' mentioned in the report are small-claims suits related to our stores' business in Israel. In the aggregate these total less than $100,000... Short sellers and competitors will not deter us from continuing to deliver the best online customer experience and to take significant market share of the beauty industry."

14:42 EDT SCWorx receives Nasdaq notice over 10Q - On May 17, 2024, SCWorx Corp. received a further notice from The Nasdaq Stock Market, LLC indicating that, as a result of not having timely filed its Form 10-Q for the period ended March 31, 2024, and because it remains delinquent in filing its Form 10-K for the year ended December 31, 2023, the company has failed to satisfy a standard for continued listing, namely Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports with the SEC. As previously disclosed, due to the SEC's Order denying BF Borgers CPA PC the privilege of appearing or practicing before the Commission as an accountant, on May 7, 2024, the board of directors of the Company dismissed BF Borgers CPA PC as the Company's independent registered public accounting firm. On May 21, 2024, the company filed a Form 8-K announcing that it has engaged a new auditor, Astra Audit & Advisory, LLC. In accordance with the SEC's guidance to companies affected by the suspension of BF Borgers, the new auditor engagement includes re-auditing the 2022 financial statements previously audited by BF Borgers. The company intends to complete the audit of its financial statements and file its 10K and 10Q as quickly as possible to regain compliance with its periodic disclosure obligations. The company intends to submit to Nasdaq a plan to regain compliance with respect to these delinquent reports no later than June 17, 2024, the due date for submitting such plan.

14:16 EDT General Dynamics VP Burns sells $3.6M in company shares - VP of General Dynamics Mark Burns disclosed the sale of 12,089 shartes of company shares for $296.59 per share on May 17, for a total transaction amount of $3,585,477.

12:46 EDT Children's Place CEO Jane Elfers to leave company, Umair named interim CEO - The Children's Place announced the departure of Jane Elfers, President and CEO, and announced the appointment of Muhammad Umair as the new President and Interim CEO, effective May 20, 2024. The company thanks Jane for her dedication to the company and wishes her well in her next chapter. Jane Elfers said, "I want to thank the entire team at The Children's Place for their hard work and dedication, and I wish them the best of luck." Umair and the coard are focused on continuing to build the company's position as a global best-in-class specialty retailer. In his capacity as Director, Umair has been immersed in the company's portfolio of brands, retail and wholesale network, and strategy to deliver great products and shopping experiences to its customers, including meeting with the leadership team and employees at the company's stores and distribution facilities, and engaging with its network of suppliers and partners. The Board is committed to a seamless transition as it conducts a search for a permanent CEO.

12:04 EDT Bloom Energy rises 9.1% - Bloom Energy is up 9.1%, or $1.18 to $14.10.

12:02 EDT Sunlands Online rises 10.2% - Sunlands Online is up 10.2%, or 90c to $9.70.

12:01 EDT NBT Bancorp announces completion of leadership transition - NBT Bancorp announced that its CEO succession plan unanimously approved by NBT's Board of Directors in January was executed with Scott A. Kingsley succeeding John H. Watt, Jr. as NBT's fifteenth President and CEO. Kingsley was also elected to NBT's Board of Directors. Watt will continue to serve on the Board and has been named Vice Chairman. NBT also announced the promotion of Joseph R. Stagliano to President of NBT Bank, N.A., the company's wholly-owned banking subsidiary, Annette L. Burns to Executive Vice President and CFO, and Shauna M. Hyle to Executive Vice President, Retail Community Banking.

12:00 EDT a.k.a. Brands falls -23.3% - a.k.a. Brands is down -23.3%, or -$5.80 to $19.04.

11:37 EDT Nintendo to acquire Shiver from Embracer Group - Nintendo (NTDOY) announced that it has entered into an agreement with Embracer Group AB (THQQF) to acquire 100% of the outstanding shares of Shiver Entertainment, Inc. and to make it a wholly owned subsidiary. Shiver is a video game development company that develops software for multiple platforms including Nintendo Switch. Since its establishment in 2012, Shiver has partnered with publishers and developers through commissions for large scale title developments, and recently, has worked on porting and developing software titles such as Warner Bros. Discovery's (WBD) "Hogwarts Legacy" and "Mortal Kombat 1." Nintendo will acquire 100% of the outstanding shares of Shiver and make it a wholly owned subsidiary. The acquisition will be completed pending satisfaction of all relevant customary closing conditions and will have only a minor effect on Nintendo's results for this fiscal year, Nintendo said. Reference Link

11:28 EDT ZimCal 'concerned' about 'excessive' pay at Medallion Financial - ZimCal Asset Management, LLC, and its affiliates BIMIZCI Fund LLC, Warnke Investments LLC and Stephen Hodges is one of the largest investors in Medallion Financial, has over $15.58M in debt and equity investment exposure and has been invested in MFIN for over 3 years. ZimCal is currently in a proxy contest to replace two Directors on MFIN's Board of Directors with two more individuals. Its common stock and debt are the only investments it has in MFIN and it does not own any other MFIN-related securities. "We believe we will prevail in this proxy contest; we believe that stockholders want change and that our nominees are the first step in that direction. ZimCal ONLY benefits through an increase in the value of MFIN and if MFIN can implement the changes ZimCal is recommending, ZimCal believes that the upside potential for the Company is tremendous. The Company has attempted to distract stockholders with speculation about ZimCal, its interests and its intentions. We are disappointed by the Company's recent personal and untruthful attacks that forced us to issue a Cease and Desist letter. However, we are encouraged by their desperation, which indicates that they are threatened by strong stockholder support for our candidates. If ZimCal's nominees are not elected, the Board would likely maintain the status quo, which has been very lucrative for the management team. If ZimCal's nominees are elected, and on behalf of stockholders, we would immediately address the excessive compensation structure of MFIN's President and management team. We believe that change must happen now. If stockholders want compensation that is fair and does not enrich management at the expense of stockholders, we need their support to make any changes. Even if ZimCal's 2 candidates are elected, we still only represent 25% of the Board, but any change to the current Board is a huge step in the right direction."

11:03 EDT PepsiCo announces expansion of electric-powered fleet across California - PepsiCo Beverages North America (PEP) announced the expansion of its electric-powered fleet across California. "In the next several months, fifty Class 8 Tesla Semi trucks will operate out of its manufacturing and distribution facility in Fresno, Calif., and 75 Ford E-Transit electric vans will step-change the electrification of its equipment services fleet across the state. The electric vehicle deployment will help the company progress toward its ambitious pep+ goal to reach net zero emissions by 2040," PepsiCo stated.

10:20 EDT Dogness Internationa trading resumes

10:15 EDT Dogness Internationa trading halted, volatility trading pause

10:08 EDT Eli Lilly pays $60M upfront for radiopharmaceutical pact with Aktis - Aktis Oncology announced a discovery collaboration agreement with Eli Lilly (LLY) to generate anticancer radiopharmaceuticals using Aktis Oncology's miniprotein technology platform. Under the terms of the agreement, Aktis will receive a $60M upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly. In addition, Aktis will be eligible to receive up to an additional $1.1B in potential preclinical, clinical, regulatory and commercial milestones, as well as tiered royalties. In exchange, Lilly will receive worldwide rights to develop radiopharmaceutical therapeutic and diagnostic products discovered by Aktis on a defined set of targets selected by Lilly. "This collaboration with Aktis Oncology builds upon our growing radiopharmaceutical capabilities and provides access to an exciting and innovative technology for creating important and differentiated radiopharmaceuticals. We look forward to collaborating with Aktis and utilizing this emerging modality to bring forward meaningful new therapies for people with cancer," said Jacob Van Naarden, President, Lilly Oncology. Shares of Eli Lilly are up 2% to $802.21 in morning trading.

10:05 EDT a.k.a. Brands falls -10.6% - a.k.a. Brands is down -10.6%, or -$2.63 to $22.21.

10:03 EDT James Hardie falls -15.2% - James Hardie is down -15.2%, or -$5.54 to $31.05.

10:01 EDT Cheetah Mobile rises 10.8% - Cheetah Mobile is up 10.8%, or 60c to $6.15.

09:59 EDT Lowe's says promotional environment 'remains stable' - Expects to be "seasonally relevant" in 2H24.

09:56 EDT HNR Acquisition announces actions to increase production - The acquired property has significant potential. HNRA has a long-term view of the property development and thus are spending the time and money to bring the field into good condition, and just as importantly, spending the time and effort to study the science to maximize our approach to developing the field. Again, we are through the initial discovery phase and are optimistic of our long-term growth and future. "Since the acquisition of the Grayburg-Jackson oil field, HNRA management has made material advancements and strategic decisions to grow the Company. We have operated the field safely and efficiently while investing monies to enhance the field condition and resulting production. Beginning in mid-November when we took over operating the field, we have had one workover rig operating to put idle and inactive wells we inherited back online. These wells were idle or inactive for various reasons," said Jesse J. Allen, VP of Operations for HNRA. "These first quarter activities enabled us to stabilize and maintain production of approximately 967 gross barrels of oil per day. We have contracted a second workover rig to increase production and capacity beginning April 2024. Additionally, we have identified 14 Seven River water injection wells that were inactive due to various repairs. We worked throughout the first quarter to complete repairs, and we expect these wells to return to injection in the second and third quarters of 2024. Our field operating team has completed extensive repairs of two tank batteries to ensure safe and reliable operations. As part of our operating plan, the engineering team has commenced a review of all wells with behind-the-pipe potential. This work prioritizes the highest-potential wells first. We expect to increase production on a quarterly basis." "We continue to invest capital through modernization and maintenance of the Grayburg-Jackson oil field, and we continue to increase production by increasing the number of wells shut in and capped by water injection. We will bring these wells back into production," said Dante V. Caravaggio, CEO and President of HNRA. "Production of oil started to increase in April and is expected to increase again in May. We are on the path of our stated goal to increase production by 400 gross barrels of oil per day by the end of 2024. With the second rig on the property, we expect an additional six additional wells to return to production in Q2. This trend should continue and increase for the remainder of the year.

09:52 EDT North European Oil Royalty Trust rises 10.9% - North European Oil Royalty Trust is up 10.9%, or 71c to $7.24.

09:50 EDT Cheetah Mobile rises 11.0% - Cheetah Mobile is up 11.0%, or 61c to $6.16.

09:48 EDT James Hardie falls -15.2% - James Hardie is down -15.2%, or -$5.56 to $31.03.

09:45 EDT Lyra Therapeutics trading resumes

09:40 EDT U-BX Technology Ltd trading resumes

09:37 EDT GT Biopharma trading resumes

09:32 EDT GT Biopharma trading halted, volatility trading pause

09:30 EDT Cheetah Net Supply Chain Service Inc trading halted, volatility trading pause

09:30 EDT U-BX Technology Ltd trading halted, volatility trading pause

09:28 EDT BAE Systems signs contract with Swedish Defense Materiel Administration - BAE Systems has signed a contract with the Swedish Defense Materiel Administration, or FMV, for new CV9035 MkIIIC vehicles, as well as associated integrated logistic support. This new contract will provide new-build CV90s to help replenish the Swedish Army's fleet. These new CV9035 MkIIICs will replace CV9040 vehicles donated to Ukraine by the Swedish government. In addition, the Swedish government is procuring more new-build CV90 vehicles to expand Ukraine capabilities. The contract will provide the opportunity for other nations to join in the procurement of CV90MkIIICs.

09:27 EDT Merit Medical launches basixSKY inflation device - Merit Medical Systems announced the US commercial release of the basixSKY Inflation Device. BasixSKY is the latest addition to Merit's comprehensive inflation device portfolio, which includes both digital and analog devices. The basixSKY is available as a standalone solution and in kits with Merit Angioplasty Packs, configured to offer complementing AccessPLUS, Honor, and PhD hemostasis valves. Designed with ease of use in mind, the new device is simple and highly responsive, creating an efficient approach to inflation. Rotational torque and handle revolutions to reach pressure are minimized, and a comfort-grip feature enables one-handed preparation.

09:25 EDT Loop Industries enters collaboration with On - Loop Industries announced its collaboration with On, the Swiss sportswear brand, and unveiled the launch of the Cloudeasy Cyclon shoe. This innovative shoe, part of On's Circular Cyclon program, is a groundbreaking achievement in sustainable footwear, featuring an upper crafted from yarn made with Loop's 100% recycled polyester fiber using the Infinite Loop fiber-to-fiber recycling technology.

09:22 EDT RenovoRx: Efficacy/drug delivery potential of TAMP improve cancer therapy - RenovoRx announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx's Trans-Arterial Micro-Perfusion or TAMP therapy platform. The data was published online in the peer-reviewed Journal of Vascular Interventional Radiology, JVIR, journal and will also be published in the print version. The manuscript is authored by Khashayar Farsad, MD, PhD of the Department of Interventional Radiology at Oregon Health and Science University, and co-authored by Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, together with other researchers, including RenovoRx's Chief Medical Officer, Dr. Ramtin Agah. ..."TAMP has the potential to provide a valuable treatment option to patients who have been diagnosed with solid tumors that may be difficult-to-treat," said Dr. Farsad. "The study shows a possible mechanism for how TAMP can increase local therapeutic tissue concentration in solid tumors that is independent from traditional catheter-directed therapy. We are awaiting final outcomes of the Phase III clinical trial, currently underway, to validate this benefit." Dr. Farsad adds, "This platform has the potential to extend across a variety of unmet needs for localized therapeutic drug delivery."

09:20 EDT Verisk Analytics announces tender offer for up to $400M of outstanding debt - Verisk Analytics has commenced a cash tender offer for up to $400,000,000 aggregate principal amount, as may be increased or decreased by the Company, of its 4.000% Senior Notes due 2025. The Company expects to fund the repurchase of notes accepted for payment in the Tender Offer with the proceeds from the issuance and sale of debt securities in a concurrent capital markets transaction. The Maximum Amount represents the aggregate principal amount of Notes subject to the Tender Offer. The Company expressly reserves the right, in its sole discretion, subject to applicable law, to increase or decrease the Maximum Amount, without extending withdrawal rights and/or terminate the Tender Offer at any time prior to the Expiration Date. If Holders tender more Notes in the Tender Offer than they expect to be accepted for purchase by the Company based on the Maximum Amount and the Company subsequently accepts more than such Holders expected of such Notes tendered as a result of an increase of the Maximum Amount, such Holders will not be able to withdraw any of their previously tendered Notes. Accordingly, Holders should not tender any Notes that they do not wish to be accepted for purchase.

09:16 EDT Lyra implements layoff of 75% of workforce, to evaluate strategic options - Lyra Therapeutics is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in addition to other cost-cutting measures. In the near term, Lyra Therapeutics will focus on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210, a bioabsorbable sinonasal implant for the treatment of chronic rhinosinusitis. Lyra continues to analyze the data from the ENLIGHTEN 1 trial, which did not meet its 24-week primary endpoint. The Company intends to use this analysis to inform its approach on the completion of the 52-week extension phase of the ENLIGHTEN 1 trial with data expected in Q4 2024 and its approach to the ongoing ENLIGHTEN 2 trial. In connection with the reduction in force, which impacts 87 employees, Lyra Therapeutics has stopped manufacturing and commercialization efforts and seeks to sublease its facilities to significantly reduce the Company's operating costs. Furthermore, Lyra has paused efforts for LYR-220. These measures are expected to extend Lyra's cash runway into 2026. As of March 31, 2024, prior to the reduction in force, Lyra Therapeutics had approximately $87.1 million in cash, cash equivalents and short-term investments, and the Company will provide an update when it reports its second quarter 2024 financial results. In parallel, the Company plans to evaluate potential strategic options to maximize shareholder value. There can be no assurance that the evaluation of strategic options will result in any transaction, or that any transaction, if pursued, will be completed on attractive terms, if at all. The Company has not set a timetable for the completion of this strategic review and does not intend, assume any obligation, or promise to publicly update or revise any information regarding the status.

09:14 EDT Crown Electrokinetics announces long-haul dark fiber construction - Crown Electrokinetics has secured a new long haul dark fiber construction project spanning approximately 250 miles from Las Cruces, New Mexico to El Paso, Texas. Corey Boaz, President of Construction for Crown Fiber Optics stated. "We are pleased to announce today's new project with Sequoia Associates. This project represents an approximate $12M gross revenue opportunity and marks our first project as a turnkey general contractor. This contract was generated through existing relationships, affirming the trust and confidence that large organizations have in the Crown team." The project is expected to commence mid-June and includes the construction and rehab of existing duct bank that runs from Las Cruces to El Paso. Crown will perform the survey, construction, fiber placement, and splicing.

09:13 EDT AMD announces availability of AMD EPYC 4004 Series processors - AMD announced the availability of the AMD EPYC 4004 Series processors that complement the existing AMD EPYC server CPU portfolio with new cost-optimized offerings that deliver enterprise-class features and leadership performance for small and medium businesses and hosted IT service providers. The AMD EPYC 4004 Series CPUs provide the price conscious buyer with enterprise-grade performance, dependability, scalability and modern security features powered by the highly efficient "Zen 4" architecture. When compared to an Intel Xeon E-2488 CPU, a server powered by a single AMD EPYC 4564P CPU delivers a 1.8x increase in performance per CPU dollar.

09:10 EDT GlobalFoundries partners with Micron, U.S. National Science Foundation - GlobalFoundries (GFS) announced a partnership with Micron Technology (MU) and the U.S. National Science Foundation, NSF, to invest in workforce development at Minority Serving Institutions, MSI, to help meet the growing workforce needs of the U.S. semiconductor ecosystem. In partnership with Micron and the NSF, the investment will support semiconductor workforce development at Historically Black College and Universities, Hispanic Serving Institutions, Asian American Native American Pacific Islander-Serving Institutions and Tribal Colleges and Universities throughout the U.S. These investments aim to diversify the semiconductor workforce and build robust talent pathways through education and career reentry initiatives.

09:09 EDT Zoom Video announces post-quantum E2EE globally available - Zoom Video Communications announced that post-quantum end-to-end encryption, E2EE, is now globally available for Zoom Workplace, specifically Zoom Meetings, with Zoom Phone and Zoom Rooms coming soon. The launch of the new security enhancement makes Zoom the first UCaaS company to offer a post-quantum E2EE solution for video conferencing. "Since we launched end-to-end encryption for Zoom Meetings in 2020 and Zoom Phone in 2022, we have seen customers increasingly use the feature, which demonstrates how important it is for us to offer our customers a secure platform that meets their unique needs," said Michael Adams, chief information security officer at Zoom. "With the launch of post-quantum E2EE, we are doubling down on security and providing leading-edge features for users to help protect their data. At Zoom, we continuously adapt as the security threat landscape evolves, with the goal of keeping our users protected."

09:08 EDT Sage Group, DonorPerfect partner for fundraising solution - Sage announces its partnership with DonorPerfect. This collaboration empowers nonprofits to streamline fundraising operations and deepen donor relationships, allowing them more time to focus on their mission impact. Sage Intacct Fundraising powered by DonorPerfect is a comprehensive, cloud-based solution that addresses one of the biggest internal challenges faced by nonprofits: a lack of process automation and organizational efficiency. By providing a seamless flow of fundraising data alongside financials, it allows for clear and transparent donation documentation - a critical factor in building trust and sustaining long-term donor relationships.

09:08 EDT Massachusetts approves Comtech to provide NG911 services - Comtech announced that the Commonwealth of Massachusetts approved executing a contract with Comtech for continued operation and maintenance of the state's Next Generation 911 or NG911 system. The new contract will have an initial five-year term from August 1, 2024 through July 31, 2029, and includes one option to renew for a five-year period through July 31 . Including the option period, the total contract value could potentially exceed $250M

09:07 EDT United-Guardian appoints Denise Costrini as marketing director - United-Guardian announced that the company has hired Denise Costrini as the company's marketing director. Ms. Costrini has more than 25 years of experience in the personal care and specialty chemicals industries, and has a Bachelor of Science degree in Industrial and Operations Engineering.

09:06 EDT Xponential divests Row House brand to Extraordinary Brands, terms undisclosed - Xponential Fitness announced it has completed the divestiture of its brand Row House to Extraordinary Brands. "The divestiture of Row House will further allow us to prioritize our time and resources on the brands that best fit our portfolio," said Brenda Morris, Interim CEO of Xponential Fitness. "We look forward to continuing to provide a high-level of support for our franchisees as we execute against our strategic growth drivers." Xponential will work closely with Extraordinary Brands to ensure a seamless transition experience for Row House franchisees. The divestiture of Row House is not expected to materially impact revenue or EBITDA in 2024, and 2024 guidance remains unchanged. Terms of the transaction were not disclosed.

09:05 EDT Nokia, Export-Import bank sign MOU on U.S. jobs, investment - Nokia announced the execution of a Framework Agreement with the Export Import bank to provide financing vehicles to partners of the company. The agreement is aimed at driving greater adoption and development of emerging wireless technologies, including 5G and subsequent wireless technologies that will continue to keep the U.S. and its partners at the forefront of emerging capabilities. Technologies also including related network and optical equipment. The agreement with the Export-Import Bank continues an ongoing emphasis for Nokia on the North American Market. In 2024, Nokia has become the first technology vendor to announce the availability of Buy America-compliant products, for broadband infrastructure projects implemented by BEAD. This follows the U.S. Governments initiative of "Buy American in meeting the digital divide" through onshoring production in the U.S. and creating U.S. based jobs. As constructed, the agreements stipulate the following: EXIM will support Nokia as authorized under the Transformational Export Program; Nokia will begin reviewing ways to increase U.S. investment, manufacturing, and job protection, continuing the company' s commitment to a strong North American presence.; Nokia agreed to study how the company can meaningfully expand U.S. jobs in the Transformational Export Area, or when possible, minimize the reduction of U.S. based jobs within the next three years. The agreement has already been executed, with the company already working toward execution of its key provisions.

09:04 EDT Xylo Technologies signs LOI to acquire AI tech company in Germany - Xylo Technologies signed a letter of intent for the strategic acquisition of a leading German company specializing in developing artificial intelligence predictive maintenance and condition monitoring technologies as well as other AI tools and technologies for various industries. This potential acquisition could mark the expansion of Xylo's portfolio to advanced AI technologies that are being integrated in various market segments and industries. The Target Company, a European leader for over 10 years in merging AI, machine learning algorithms with advanced hardware solutions, turning existing processes into more efficient and environmentally friendly. The Target Company is already providing services to multiple leading global entities in sectors including aerospace, aviation, transportation, real estate, security, and more, demonstrating its various areas of ability and expertise. Its unique approach of making manufacturing equipment smarter and more connected aligns with Xylo's strategy of growing and developing high-growth potential technologies. Pursuant to the LOI, subject to the closing, Xylo will pay a down payment of 1.5 million Euros and will initially hold 51% of the Target Company's outstanding shares. The remaining 49% will be acquired with the determination of the final price of the transaction based on the actual 2024 EBITDA results.

09:02 EDT LPL Financial welcomes Auctus Legacy Private Wealth Management - LPL Financial announced that financial advisors Alain Verhille and James S. Wood have joined LPL Financial's high-net-worth-focused employee affiliation model, LPL Private Wealth Management, to launch Auctus Legacy Private Wealth Management. The advisors reported serving approximately $705 million in advisory, brokerage and retirement plan assets and join LPL from Merrill Lynch. Based in Oklahoma City, Okla., Senior Vice President, Wealth Management Advisor Verhille and Managing Director, Wealth Management Advisor Wood are longtime business partners with more than 50 years of collective industry experience. The advisors serve a primarily high-net-worth clientele, focusing on comprehensive planning that seeks to optimize wealth and reduce risk for multi-generational families. They are joined by licensed Certified Senior Advisors Erikka Moore and Kathy Isernhagen.

08:55 EDT Lyra Therapeutics trading halted, news pending

08:48 EDT Silo Pharma announces study results for depession remission, relapse prevention - Silo Pharma announced new results in its research focused on depression remission and relapse prevention. A recent study under the Company's sponsored research agreement with Columbia University suggested a potentially innovative drug formulation that targets biochemical pathways associated with mood regulation previously unexplored by the Company which showed positive effects including marked improvements in patient mood stability without the side effects commonly associated with existing antidepressants. "The recently completed study demonstrated marked improvements in mood stability, which we see as a potentially significant development for combatting depression and preventing relapse," said Silo CEO Eric Weisblum. "While advancing our SPC-15 program in PTSD to the clinic remains our top pipeline priority, we are excited about these encouraging new results and the additional potential for treating millions of people affected by depression which could ultimately expand our pipeline." Silo has taken SPC-15 through pre-clinical development and is preparing to submit a pre-investigational New Drug Application to the FDA for the drug's lead indication in PTSD. Silo has exercised its option to license SPC-15 from Columbia University, pursuant to a sponsored research and option agreement originally established in 2021. Under the terms of the license agreement, which is currently being finalized, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. The Company expects to complete and enter into the exclusive license agreement in the first half of 2024.

08:42 EDT PodcastOne announces LADYGANG 'You Never Forget Your First' tour - PodcastOne announced the LADYGANG podcast presents the "You Never Forget Your First" tour presented by CLEARSTEM. With tour stops across North America, including cities such as New York, Boston, and Atlanta, LADYGANG, hosted by Keltie Knight, Becca Tobin and Jac Vanek, kick off their tour August 9, 2024 in Austin, Texas before wrapping up on the West Coast in December of this year.

08:40 EDT Ferrari announces settlement of notes offering - Ferrari announces the settlement of the offering, previously announced, of Euro 500 million in aggregate principal amount of 3.625% notes due on 21 May 2030, with an issue price of 99.677%. The net proceeds of the offering were approximately Euro 497 million after payment of offering costs and related expenses. The Notes have been admitted to the Official List of Euronext Dublin and to trading on the regulated market of Euronext Dublin. The prospectus related to the Notes, dated 15 May 2024, was approved by the Central Bank of Ireland and it has been published on the Ferrari N.V. corporate website together with other relevant documents.

08:40 EDT Sprout Social down 8% after saying company not in talks to go private - Shares of Sprout Social are down $2.68, or 8%, to $29.13 in pre-market trading after the company stated that "currently, there is no process in place to sell or take the company private."

08:39 EDT Earlyworks announces business alliance with Relic - Earlyworks announces a business alliance with Relic to promote new business development utilizing Web3 technology. Under this alliance, Earlyworks' business development assets utilizing Web3 cutting-edge technology will be combined with Relic's organizational capabilities and expertise in all phases and areas of new business development, to jointly support new business development utilizing Web3 cutting-edge technology. Earlyworks and Relic will jointly develop and widely provide a new business development scheme that addresses business issues, brand damage risks, legal and financial risks, etc., faced by large companies by linking DUALii, an incubation partner platform that allows companies to build optimal co-creation systems through flexible involvement schemes and diverse exit strategies with Earlyworks' proprietary blockchain technology.

08:37 EDT Palisade Bio presents preclinical data on PALI-2108 at DDW 2024 - Palisade Bio announced the presentation of positive preclinical data from PALI-2108, an orally administered, locally acting colon-specific Phosphodiesterase-4 inhibitor prodrug in development for patients affected by UC, at DDW 2024 being held in Washington, D.C., May 18-21, 2024. The poster titled, "Local Bioactivation and efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment," is being presented by Dr. Mitch Jones as part of the Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation session being held today, May 21, 2024. The preclinical data highlighted in the poster reveal significant advancements in assessing on-target PDE4 binding within colon tissue homogenates when dosed with apremilast, PALI-2108, or Vehicle, utilizing a classic cellular thermal shift assay to detect changes in thermal stability. To comprehensively evaluate PALI-2108's efficacy across various doses, researchers employed an acute colitis model in mice induced by 4% DSS in drinking water from Day 1 to Day 8. Mice received twice-daily treatments of PALI-2108 at 20, 40, and 80 mg/kg/dose BID, while cyclosporin A and apremilast were administered at 40 and 12.5 mg/kg/dose BID, respectively. The assessment of DSS-induced colitis included monitoring Body Weight score, Stool Consistency score, and Fecal Blood score from Day 1 to Day 8, with evaluations conducted 1 to 2 hours post-dosing. Overall disease state was measured using a Disease Activity Index score, calculated by pooling the three in-life scores, assessed daily from Days 1 to 8. Furthermore, a single oral dose of the prodrug PALI-2108 at 43 mg/kg and active PALI-0008 at 0.1, 0.3, 1, and 3 mg/kg was administered to dogs, with a focus on monitoring key clinical adverse events, including emesis. Remarkably, the PALI-2108 prodrug prevented emesis observed with lower doses of the PDE4 active moiety in the model, demonstrating an enhanced therapeutic window. Key Findings: PALI-2108 demonstrates similar target engagement to the PDE4 inhibitor, apremilast, which is approved for use in psoriasis and psoriatic arthritis. In a DSS colitis mouse model, PALI-2108 significantly prevented colon length reduction in dose dependent manner, and showed dose dependent improvements in body weight score, stool consistency score, fecal blood score, overall disease activity index score, and AUC of DAI over the course of the study. Importantly, PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in UC patients. No systemic toxicity in dogs and large therapeutic window due to local activation.

08:36 EDT Reborn Coffee announces LOI to acquire majority stake in Derin Lezzetler - Reborn Coffee announced that it has signed a Letter of Intent, LOI, to acquire a 55% majority stake in Derin Lezzetler, a leading artisan snack and frozen bakery producer based in Istanbul, Turkey. "This Letter of Intent aligns perfectly with our vision to enhance our product offerings and cater to the evolving needs of our customers," said Farooq Arjomand, Chairman of Reborn Coffee. "Derin Lezzetler's commitment to quality and innovation in the health food sector presents a valuable addition to our business. Furthermore, this partnership will accelerate our plans to expand our presence in the US market, introducing these artisan and health-focused products to American consumers."

08:34 EDT Mangoceuticals to introduce oral Semaglutide, Tirzepatide - Mangoceuticals announces the development of proprietary oral formulations of Semaglutide and Tirzepatide to aid in weight management. These innovative drugs, currently available predominantly in injectable form, have demonstrated remarkable efficacy in clinical trials. MangoRx's new oral formulations are poised to revolutionize the weight loss market and capture significant market share. "We are thrilled to introduce 'Slim' and 'Trim', MangoRx's oral formulations of Semaglutide and Tirzepatide, to the weight loss market," said Jacob Cohen, CEO and Co-Founder of MangoRx. "Our goal is to provide patients with a convenient and effective way to manage their weight and improve their overall health. We believe that these oral formulations have the potential to significantly impact the lives of millions of people worldwide."

08:33 EDT Massimo expanding manufacturing facility in Garland, Texas - Massimo announced an expansion of its manufacturing facility in Garland, Texas, to support increased production across its motor and marine product verticals. The expansion will add 90,000 sq. ft. to the existing facility. The Garland location will continue to manufacture its Pontoon Boats in its now 376,000 sq. ft. facility, of which 260,000 sq. ft. is dedicated to Massimo Motor Sports and 96,000 sq. ft. to Massimo Marine. The facility expansion is the first in a series of expansion projects to accommodate the company's growth initiatives.

08:32 EDT Biodexa Pharmaceuticals announces Phase 2 results of eRapa - Biodexa Pharmaceuticals announces that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis are scheduled for presentation at the prestigious 2024 Digestive Disease Week annual meeting in Washington D.C.. Carol Burke, MD, the Principal Investigator, will present the six month data in a podium presentation at the meeting. The study was partially supported by $20M in grant funding from the Cancer Prevention and Research Institute of Texas under product development awards DP22053 and DP190069. Results of the Phase 2 study at six months: In the duodenum, 14/18 patients were non-progressors with 11/18 of these patients with PR. In the colorectum, 25/29 patients were non progressors including all with an intact colon; of these 15/29 patients demonstrated PR including 4 with an intact colon. Only two drug-related Grade 3 Serious Adverse Events occurred during the trial, and 97% of patients remained on treatment at six months.

08:27 EDT Ardelyx presents additional data at 2024 DDW conference on IBSRELA - Ardelyx announced that data supporting additional positive clinical observations of IBSRELA was presented at the 2024 Digestive Disease Week Conference, DDW, currently taking place in Washington, D.C. IBSRELA is a first-in-class treatment that is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation, IBS-C, in adults. "We are thrilled to share new data on the safety and efficacy of IBSRELA in adults with IBS-C at this year's DDW Conference as we seek to continually elucidate its potential benefit in this patient population. These data provide additional information for both patients and prescribers as they consider IBSRELA as a potential new treatment option when symptoms of IBS-C persist despite current therapies," said Laura Williams, MD MPH, chief medical officer of Ardelyx. "These analyses provide further evidence of the role IBSRELA could play, with its novel mechanism of action, in the treatment of IBS-C."

08:26 EDT J&J reports Tremfya demonstrates superiority versus Stelara in Crohn's trial - Johnson & Johnson announced the first Phase 3 results for Tremfya in adult patients with moderately to severely active Crohn's disease, which demonstrated superiority of both subcutaneous maintenance doses versus placebo and ustekinumab. Data showed that both maintenance doses of Tremfya met the composite co-primary endpoints compared to placebo in each individual study. In results versus ustekinumab, both doses of Tremfya demonstrated statistically significant and clinically meaningful differences on all prespecified pooled endoscopic endpoints. These findings were featured as a late-breaking oral presentation at Digestive Disease Week, or DDW, J&J noted. "The Phase 3 GALAXI program, comprised of two rigorous, double-blind studies with secondary endpoints comparing TREMFYA to ustekinumab, reiterate our dedication to addressing the needs of patients with Crohn's disease and our deep scientific expertise in inflammatory bowel disease and focused innovation in the IL-23 pathway. These findings demonstrate the promise of TREMFYA for patients living with moderately to severely active Crohn's disease compared to conventional and advanced therapies," said David Lee, M.D., Ph.D., Global Therapeutic Area Head Immunology, Johnson & Johnson Innovative Medicine.

08:26 EDT Dr. Reddy's, Alvotech enter into collaboration for commercialization of AVT03 - Alvotech (ALVO) and Dr. Reddy's Laboratories, wholly-owned subsidiary of Dr. Reddy's Laboratories (RDY), announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech's biosimilar candidate to Prolia and Xgeva. The collaboration combines Dr. Reddy's global commercial presence with Alvotech's proven capabilities in developing biosimilars for markets worldwide. Erez Israeli, Chief Executive Officer of Dr. Reddy's, said: "We are pleased to collaborate with Alvotech to make this denosumab biosimilar available to patients in the U.S., Europe and UK. Over the years, we have created a portfolio of biosimilar products, which are marketed in several emerging markets. Most recently, we launched bevacizumab, our first biosimilar in the UK. This strategic collaboration augments our growing portfolio of biosimilar offerings, and progresses our biosimilar journey further into the highly regulated markets. We look forward to leveraging our strong commercial capabilities in these markets to ensure patients receive access to best-in-class therapies and affordable treatment options."

08:25 EDT Bionano Genomics announces three publications on OGM - Bionano Genomics announced the publication of three studies which collectively illustrate the continued development of data supporting the utility of optical genome mapping, OGM, in cell and gene therapy applications. In all three publications, the authors note OGM's potential to provide a comprehensive landscape of genome structure and to assess genome integrity due to the workflow's ability to detect structural variants with higher sensitivity and resolution than standard cytogenetic techniques. Key Findings and Takeaways: In a publication from Nino Jesus University Children's Hospital, researchers analyzed different strategies to improve the efficacy of chimeric antigen receptors in solid tumors. OGM analyzed PB, 45RA and CB CAR-T products after 8 days of culture and compared with T cells from donor samples at day 0 to look for new variants, including aneuploidies; OGM revealed a single event with potential pathogenic implications in one of the analyzed donor sources, as well as additional variants of uncertain significance. The publication from Ruhr-University Bochum covered the use of OGM following gene editing to assess the genome integrity of two CRISPR/Cas9-edited hiPSC lines used for studying Alzheimer's disease. OGM revealed multiple aberrations that affected a large number of genes but were found to have mild impact on the ability of hiPSCs to develop cerebral organoids. Edited hiPSCs were not found to have major phenotypic changes but one edited cell line showed potential neuroectodermal differentiation impairment. OGM confirmed on-target edits and did not detect off-target edits. The publication from Janssen details research into the Apolipoprotein E genotype, which is the strongest risk factor for late-onset Alzheimer's disease. OGM confirmed the absence of off-target effects above 500 bp in the cell lines

08:23 EDT Morphic demonstrates real-time visual of small molecule alpha4beta7 inhibition - Morphic Therapeutic announced the presentation of new data, using Spinning Disk Intravital Microscopy, IVM, that provides real-time, in vivo visualization of the impact of alpha4beta7 inhibition on lymphocyte trafficking in mouse gut-associated lymphoid tissues, GALT. These data were presented in a poster session at Digestive Disease Week, DDW, 2024 meeting. This real-time footage and the associated data for B cell movement clearly demonstrate that MT-108, a potent and selective small molecule alpha4beta7 inhibitor, leads to increased velocity and flux of rolling lymphocytes. This activity subsequently prevents lymphocyte migration into gut tissue, including Peyer's patches, which is a key component of inflammatory bowel disease. Notably, MT-108 impacted B cell trafficking with similar speed of onset and efficacy as the anti-alpha4beta7 blocking antibody DATK32, a murine analog of the monoclonal antibody vedolizumab. The onset and extent of alpha4beta7 inhibition can be visualized by the increased velocity of B cells when comparing the lymphocyte movement prior to compound administration. In the absence of inhibitor, cells are slowed by their binding of alpha4beta7 with the ligand MAdCAM-1. Following administration of MT-108, the immune cells transit more quickly through the vessel as a result of inhibition of alpha4beta7-mediated adhesion and fewer cells are seen affixed to vessel walls.

08:21 EDT Axalta Coating announces partnership with Solera - Axalta announced a partnership with Solera, a global leader in vehicle lifecycle management. Through this partnership, Axalta's conventional and Fast Cure Low Energy, FCLE, refinish paint systems will be integrated into Solera's Sustainable Estimatics platform, enabling Axalta customers to estimate their CO2 emissions per repair, while considering repair methods, paint application process, and drying conditions. "We are excited to partner with Solera and introduce a new solution for our customers," said Troy Weaver, President of Global Refinish at Axalta. "This technology aligns with Axalta's ongoing commitment to sustainability as we set out to become Carbon Neutral by 2040 and was designed with our customers in mind to help them achieve their sustainability goals. By providing a CO2 emission estimate per repair, bodyshops can make data-driven decisions to help lower their carbon footprint while also benefiting their bottom line."

08:20 EDT Kanzhun director Shangyu Gao resigns, Mengyuan Dong appointed to board - KANZHUN announced that Ms. Shangyu Gao has resigned as an independent non-executive director of the Company in order to devote more time to her other personal business commitments, effective on May 21, 2024. In addition, with effect from May 21, 2024, Ms. Mengyuan Dong has been appointed as an independent non-executive director of the Company, the chairman of the audit committee, a member of the compensation committee and a member of the corporate governance committee. Ms. Mengyuan Dong, aged 38, is a financing and investment expert with over 12 years of experience in capital market industry. Ms. Dong previously held the position of a director at Huaxing Growth Capital from July 2022 to May 2024

08:18 EDT Tonix announces findings from initial phase of EVERSANA market opportunity - Tonix Pharmaceuticals announced that EVERSANA Life Science Services completed the initial phase of an assessment of the U.S market opportunity for Tonmya, a potential new first line therapy for the management of fibromyalgia. Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya. Specifically, EVERSANA is working with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market strategy. "The primary research and analysis conducted by EVERSANA provides valuable insights and informs the vision for the commercialization of Tonmya," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "We are excited to refine our business strategy for the anticipated launch of Tonmya in 2025. It has been approximately fifteen years since patients suffering with fibromyalgia have been provided a new therapeutic option. The market research conducted by EVERSANA with physicians indicates a continued high unmet need, with the need ranked greater than 4.0 on a 5-point scale."

08:14 EDT Kandi 10K all-electric UTV model achieves EU EEC certification - Kandi Technologies Group announced the certification of its 10K all-electric UTV model by the European Economic Community. This achievement confirms that the product meets the European Union's high standards for safety, quality, and performance, preparing it for its market debut within the EU.

08:12 EDT BASF to pay $316.5M in settlement with U.S. public water systems - On May 20, 2024, BASF Corporation, the North American affiliate of BASF SE, agreed to a settlement with a nationwide class of public water systems that detected PFAS in their drinking water sources, which they allege to be associated with the use of Aqueous Film Forming Foam products. Some of the AFFF products at issue in the litigation were made using a surfactant produced by Ciba Specialty Chemicals , which BASF acquired in 2009. In 2003, years before BASF acquired Ciba, Ciba sold that business line to another company. Under the terms of the agreement, BASF has agreed to contribute $316.5 million. The settlement releases these claims against BASF, Ciba, and other related corporate entities. This settlement was entered in connection with the previously disclosed AFFF multi-district litigation being overseen by the United States District Court for the District of South Carolina. BASF will pay $4 million on or about July 15, 2024, and $312.5 million on March 1, 2025. BASF has a significant amount of insurance through a number of insurers and is pursuing recovery of its settlement payment under those policies. There are still several procedural and legal steps that must occur before the settlement is final and payments are made. The settlement is subject to approval by the MDL Court and other contingencies, and that process is expected to take several months. The class of public water systems included in this settlement broadly includes any public water system that detected PFAS in its drinking water sources as of May 15, 2024. The following systems are excluded from the settlement class: water systems owned and operated by a State or the United States government; systems that have not detected the presence of PFAS as of May 15, 2024; small transient water systems; and privately-owned drinking water wells. The settlement does not resolve claims of public water systems that request exclusion from the class pursuant to the process to be established by the MDL Court, although it does provide BASF with the option of terminating the settlement if too many public water systems elect to opt out. It also does not resolve potential future claims of public water systems that detect PFAS in their water systems for the first time after May 15, 2024, or certain claims not related to drinking water, such as separate alleged claims relating to real property damage or stormwater or wastewater treatment. Finally, this settlement does not affect the other categories of cases that remain at issue in the AFFF MDL, such as personal injury cases, property damage cases, other types of class actions, claims brought by state or territory attorneys general, or other types of damages alleged to be related to the historic use of AFFF. The settlement does not constitute an admission of liability or wrongdoing by BASF or Ciba. If the MDL Court does not approve the agreement or certain terms are not fulfilled, BASF will continue to defend itself in the litigation. BASF also intends to continue to defend itself in all remaining AFFF matters.

08:11 EDT Enphase Energy launches IQ8 Microinverters in Finland - Enphase Energy announced that it has entered the solar market in Finland with the introduction of IQ8 Microinverters, with peak output AC power of up to 384 W. "We're excited to continue our expansion into Europe with our new IQ8 Microinverter-based solar energy systems," said Sabbas Daniel, senior vice president of sales at Enphase Energy. "Our industry-leading products combined with our dedication to excellent customer service will help installers in the region expand their businesses without sacrificing quality."

08:08 EDT CareCloud promotes Williams to Chief Operating Officer - CareCloud announced the promotion of Crystal Williams as its new chief operating officer with the goal of further streamlining operations and supporting the Company's achievement of its profitability and free cash flow objectives. Williams most recently served as VP Client Operations for the Company.

08:08 EDT Lipella announces receipt of FDA Type-C meeting guidance on LP-10 - Lipella Pharmaceuticals announced the receipt of U.S. Food & Drug Administration, FDA, Type-C meeting guidance regarding the LP-10 clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024. The FDA provided preliminary agreement on Lipella's overall trial design, including objectives, safety monitoring, control group monitoring, the dosing protocol, the primary efficacy endpoint, and sample size considerations. Lipella's Chief Medical Officer, Dr. Michael Chancellor, stated, "We can now proceed with the confidence that our Phase 2b study design can successfully meet its regulatory objectives. This clarity significantly advances our value proposition."

08:07 EDT Guardion Health: Largest stockholder votes in favor of Special Meeting proposals - Guardion Health Sciences announced that Mr. Bradley Louis Radoff, who, together with his affiliates, holds approximately 18.92% of the Company's issued and outstanding shares of common stock, has voted in favor of the Company's proposals to approve the sale of the Company's Viactiv brand and business and the Plan of Liquidation and Dissolution, all as described in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission on April 8, 2024. The Company also announced that, based on the information currently available to it, if the Company's stockholders vote to approve the sale of the Company's Viactiv brand and business and the proposed Plan of Liquidation and Dissolution, it estimates that the total amount distributed to its stockholders will range from approximately $9.00 and $11.00 per share of common stock based on the Company's number of shares of common stock currently issued and outstanding. The actual amount to ultimately be distributed is subject to all of the risks, discussion and disclosures included in the Proxy Statement. The timing and amount of the total distributions will depend upon a number of factors as described in the Proxy Statement, including, without limitation, the approval of the stockholders of both the sale of the Viactiv business and the Company's Plan of Liquidation and Dissolution, the closing of the agreement to sell the Viactiv business on the terms contained in the Purchase Agreement on or before June 30, 2024, the actual expenses incurred by the Company in connection with closing of the Purchase Agreement, the timing of the resolution of matters for which the Company has established a contingency reserve, the amount to be paid in satisfaction of such contingencies, the obligations satisfied and provisions made during the liquidation and winding-up process, the absence of any unexpected claims against the Company, as well as the Company's ability to convert its remaining assets to cash on a timely basis. The Company has attempted to estimate reasonable reserves for such liabilities, obligations, expenses and claims against it. However, those estimates may be inaccurate, which may cause the amount the Company distributes to its stockholders to be substantially less than the amount it currently estimates. Stockholders are advised to carefully read the Proxy Statement.

08:06 EDT Udemy names Rob Rosenthal as Chief Revenue Officer - Udemy announced it has appointed Rob Rosenthal as Chief Revenue Officer to lead Udemy Business, effective June 3, 2024. Rosenthal brings over 25 years of experience in the software industry, helping high-growth organizations accelerate revenues while scaling globally. Rosenthal will report directly to Udemy's President and CEO, Greg Brown, and will oversee the entire Udemy Business team. In this role, Rosenthal will have global responsibility for Udemy Business' enterprise sales strategy, with a focus on driving sustainable growth through acquiring new customers, deepening relationships with existing customers, and expanding into new geographies.

08:04 EDT Eli Lilly's mirikizumab shows efficacy in Crohn's disease - Eli Lilly reported results from its pivotal Phase 3 VIVID-1 study in which patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful improvements across multiple clinical and endoscopic endpoints at one year with mirikizumab compared to placebo. Data from this study will be presented at Digestive Disease Week in Washington, D.C. from May 18-21. Mirikizumab achieved both co-primary endpoints and all major secondary endpoints at Week 52 compared to placebo, including: proportion of participants achieving clinical response by patient reported outcomes at Week 12 and clinical remission at Week 52 vs. placebo. At one year, clinical remission and endoscopic response were achieved by 54.1% and 48.4% of patients on mirikizumab, respectively. Notably, of the patients who received mirikizumab, 56.7% of bio-naive and 51.2% of bio-failed patients achieved clinical remission at Week 52. The overall safety profile of mirikizumab in patients with moderately to severely active Crohn's disease was consistent with the known safety profile in patients with ulcerative colitis. The frequency of serious adverse events was greater in placebo than mirikizumab. Lilly submitted a supplemental Biologics License Application for mirikizumab in Crohn's disease to the FDA and EMA this year. Additional global regulatory submissions are planned.

08:03 EDT ABM expands EV infrastructure capabilities to service fleets - ABM is expanding its capabilities and focus to serve comprehensive fleet electrification, as eCommerce, distribution, last mile, airports, stadiums, municipal and public transit clients seek to scale the electrification of their fleets over the coming years. ABM will showcase its fleet electrification solutions at the Advanced Clean Transportation Expo May 20 through 23 in Las Vegas. As a strategic partner for facility operators across the U.S., ABM is developing its solution offerings to support scalable electrification for both commercial and public infrastructure fleets through five operating essentials for optimal fleet performance: Design, engineering, and installation; Onsite, predictive, and proactive maintenance; Enhanced network reliability; Hardware interoperability; Microgrids and power resiliency and storage.

08:03 EDT Nutanix, EnterpriseDB expand partnership - Nutanix and EnterpriseDB announced an expanded partnership that aims to enable customers to harness the power of PostgreSQL to support their applications and workloads. The combined solution brings together Nutanix Database Service's developer self-service and database automation with EDB's performance and high availability, enterprise security, and Oracle compatibility capabilities.

07:40 EDT ARway.ai acquires Map Dynamics from Nextech3D.AI for 4M shares - ARway.ai (ARWYF) has agreed to acquire Map Dynamics in exchange for or 4M shares valued at over $1M based on Fridays closing price of $0.26/share. Map D is a real world Mapping Software company that has over 400 clients generating $1.2M in annual revenue with $250,000 in EBITDA over the past 12 months ending in March, 2024. Map Dynamics is a well-established event technology company wholly owned by Nextech3D.ai (NEXCF). This strategic acquisition combines two interactive mapping platforms expected to fast track ARway's product development roadmap and add significant new revenue channels and growth opportunities as both companies focus exclusively on mapping. With the strategic combination of ARway and Map Dynamics technologies, ARway is set to enhance its platform and expand its market offerings significantly. This merger will merge ARway's augmented reality navigation capabilities with Map Dynamics' expertise in creating detailed venue maps and floor plans.

07:38 EDT Nextech3D.AI sells Map Dynamics to ARway for 4M shares - Nextech3D.AI (NEXCF) has divested its Map Dynamics business, a non-core floor plan mapping software unit, to ARway (ARWYF), in exchange for or 4M shares valued at over $1M based on Fridays closing price of $0.26/share. This transaction brings Nextech3D.ai's ownership stake in ARway to almost 50% allowing it to share in a substantial amount of ARway's and Map D's upside without having to manage the business itself day to day. This move streamlines Nextech3D.ai's operations, allowing the company to focus exclusively on its high margin-profitable generative AI-powered 3D modeling technology. The closing is expected to happen in the first half of June. The divestiture not only advances Nextech3D.ai's position in 3D modeling and AI technology but also enhances ARway's financial standing, contributing approximately $1.2M in revenue and about $250,000 in free cash flow, bolstering its growing spatial mapping operations creating a win-win combination for shareholders of both companies. This strategic move allows the company to focus on further developing its core competencies in 3D and generative AI and underline Nextech3D.ai's commitment to leading the evolution of digital commerce through advanced 3D and AI modeling technologies.

07:37 EDT Curtiss-Wright introduces three-year financial targets - For FY24-FY26, the company expects total organic revenue CAGR above 5%; operating Income Growth greater than revenue growth, implying continued operating margin expansion; top quartile margin performance; EPS CAGR above 10%; free cash flow conversion above 105%, based on more normalized capital expenditures and targets reflect base year of 2023, and do not include an AP1000 order in this timeframe. "This is an exciting time for Curtiss-Wright as we leverage our strong track record of operational excellence and financial discipline, and continue to build momentum in our Pivot to Growth strategy," said Lynn Bamford, chair and CEO of Curtiss-Wright Corporation. "Our technologies and portfolio of solutions are incredibly well-aligned with customer and industry needs and growth trends in all our core end markets. We expect to deliver incremental operating margin expansion and strong free cash flow generation, while making strategic investments in research and development to accelerate our long-term organic growth. Overall, we are confident in our ability to achieve our new 3-year financial targets and deliver significant long-term value for all of our stakeholders."

07:35 EDT Bombardier announces launch of new issuance of senior notes - Bombardier has launched an offering of $500 million aggregate principal amount of new Senior Notes due 2032. Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, to fund the repayment and/or retirement of outstanding indebtedness, including the redemption of $240 million aggregate principal amount of its outstanding 7.125% Senior Notes due 2026 and the redemption of $300 million aggregate principal amount of its outstanding 7.875% Senior Notes due 2027, and to pay accrued interest and related fees and expenses. As of the date hereof, there is $504 million aggregate principal amount outstanding of the 2026 Notes and $1,433 million aggregate principal amount outstanding of the 2027 Notes. Consummation of the offering of the New Notes, the Conditional 2026 Notes Redemption and the Conditional 2027 Notes Redemption are subject to market and other conditions, and there can be no assurance that Bombardier will be able to successfully complete these transactions on the terms described above, or at all. The Conditional 2026 Notes Redemption and the Conditional 2027 Notes Redemption are expected to be subject to certain conditions, including the completion of the offering of the New Notes.

07:35 EDT Bread Financial appoints John Fawcett to board of directors - Bread Financial Holdings announced that John Fawcett, a seasoned financial services executive, has joined the Company's board as an independent director. Fawcett was elected at the Company's Annual Meeting of Stockholders, held Tuesday, May 14, along with nominees Ralph Andretta, Roger Ballou, John Gerspach, Jr., Rajesh Natarajan, Joyce St. Clair, Timothy Theriault, Laurie Tucker and Sharen Turney, each of whom served as Bread Financial directors during the 2023-2024 term. In connection with his appointment, Fawcett will also serve as a member of the board's Audit and Nominating & Corporate Governance committees.

07:34 EDT Mattr Corp. reports voting results from annual meeting - Mattr Corp. announced in accordance with Toronto Stock Exchange requirements, the voting results from its Annual Meeting held virtually on May 15, 2024. A total of 49,829,154 common shares were voted at the meeting representing 75.11% of the votes attached to all outstanding shares. Shareholders voted in favour of all items of business before the meeting, including the election of all director nominees.

07:31 EDT Leggett & Platt names Karl Glassman as CEO, succeeding Mitch Dolloff - Leggett & Platt announced that its Board of Directors has appointed Karl Glassman as President and CEO, effective immediately. Karl will continue to serve as Board Chairman. This follows the decision by Mitch Dolloff to resign as CEO and a member the Board, also effective immediately, having mutually agreed with the Board that now is the right time for a change in leadership at Leggett & Platt. Mitch will serve in a consulting capacity for one year to assist in the transition. Karl has served as an executive director and non-executive director on the Leggett & Platt Board since 2002, and previously served as CEO from 2016 to 2021. Karl has served in other various leadership capacities with the company over his 42-year tenure, including COO and President of the former Residential Furnishings segment.

07:30 EDT Macy's says FY24 guidance does not include credit card late fee rule - The company said, "The company's outlook excludes any potential impact from the credit card late fee ruling, which was stayed on May 10, 2024." Comments taken from Q1 investor presentation slides.

07:20 EDT Xperi: 3rd independent proxy advisory firm supports all Xperi board candidates - Xperi announced that a third independent proxy advisory firm, Egan-Jones Ratings Company has joined Institutional Shareholder Services and Glass, Lewis in recommending that Xperi stockholders vote "FOR" all of the Company's director nominees on the BLUE proxy card ahead of the Company's 2024 Annual Meeting of Stockholdersc, to be held on May 24. One of the Company's stockholders, Rubric Capital Master Fund , has nominated two candidates to replace half the company's independent directors on the Xperi Board of Directors . Following the same recommendation as ISS and Glass Lewis, Egan-Jones concluded that "change in leadership is unwarranted as it would disrupt the transformation that is currently underway," and recommended that "voting FOR ...nominees is in the best interest of the Company and its shareholders." Specifically, Egan-Jones highlighted Xperi's "compelling... transformation strategy": "Since the Adeia spin-off in 2022, Xperi has experienced a significant shift... and has paved the way to capitalize on its core segments."

07:16 EDT China Yuchai launches 50 green energy buses in Beijing - China Yuchai International announced that 50 green energy buses equipped with Yuchai Xingshunda hydrogen fuel cells debuted at a ceremony in Beijing. Yuchai Xingshunda is a 65% owned joint venture of Yuchai established in 2022 with Beijing Xing Shun Da Bus Co., Ltd. for the development, manufacturing and sale of fuel cell powertrain systems as well as core fuel cell power system components.

07:14 EDT Carbon Streaming announces update on status of Rimba Raya Verra account - Carbon Streaming provided an update on the status of the Rimba Raya project's Verra account and its Forest Utilization Business License. On May 17, 2024, Verra temporarily suspended InfiniteEARTH Limited and its Indonesian subsidiary PT InfiniteEARTH Nusantara, the project proponent of the Rimba Raya project, registry account for the Rimba Raya project. Verra has written to InfiniteEARTH, with whom the Company had previously entered into the carbon credit streaming agreement covering the Rimba Raya project, to seek clarification on several matters, including the revocation of the Concession License by the Indonesian Government's Ministry of Environment and Forestry, and the status of InfiniteEARTH's role in the Rimba Raya project and its relationship with PT Rimba Raya Conservation, the local concession holder for the Rimba Raya project. InfiniteEARTH was given seven days to respond, after which Verra will determine whether any further action is required under its program rules and requirements. On May 16, 2024, the State Administrative Court of Jakarta issued an interlocutory decision for the MOEF to suspend the implementation of the MOEF decree in respect of the revocation of the Concession License. This suspension will allow activities at the Rimba Raya project to resume until a final and binding decision on the revocation of the Concession License. As previously announced, a final decision from the State Administrative Court of Jakarta is currently anticipated during June 2024. If the parties appeal the decision, the suspension would remain in place during the appeal process until there is a final and binding decision that has permanent legal force, unless there is another stipulation from the court that states otherwise. As a result, the duration of the suspension is unknown at this time. For the Company's most recently completed financial period, the three month quarter ended March 31st, 2024, the Company determined the fair value of the Rimba Raya Stream to be nil due to the Concession License revocation. The Company will re-evaluate the fair value of the Rimba Raya Stream in the event there is a change in the facts and circumstances surrounding the Rimba Raya project, the revocation of the Concession License and the Indonesian national carbon emission regulations. The Company is continuing to evaluate all legal avenues to protect its investment in the Rimba Raya project and to strictly enforce its legal and contractual rights under the Rimba Raya Stream. In addition, Carbon Streaming will also continue to work closely with InfiniteEARTH on its active engagement with its local partners, the MOEF and the Indonesian Government, to attempt to preserve the continuity of the Rimba Raya project.

07:13 EDT Avadel Pharmaceuticals appoints Amin to board of directors - Avadel Pharmaceuticals announced the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA.

07:11 EDT Ecarx announces Lynk & Co 07 EM-P sedan began deliveries in China - ECARX Holdings congratulated Lynk & Co on the first deliveries of the Lynk & Co 07 EM-P sedan, which is integrated with ECARX's full-stack solution for digital cockpit and ADAS including Antora 1000 Pro, Skyland Pro, and Flyme Auto. The EM-P 07 began deliveries on May 17, 2024. The Lynk & Co 07 EM-P was officially unveiled at the Beijing Auto Show 2024 in April, where it attracted immediate and significant interest from consumers, with orders in excess of 10,000 vehicles. The 07 EM-P is the second Lynk & Co model to launch with ECARX's full-stack solution, following the highly successful launch of the 08 EM-P in September 2023. Over the Chinese Labor Day holiday at the start of May 2024, combined orders for the Lynk & Co 08 EM-P and the 07 EM-P surpassed 7,800 vehicles.

07:10 EDT Air Industries receives order of $2.4M for landing gear - Air Industries Group announced it has received a $2.4M order for spare landing gear assemblies to be used on the E-2C Hawkeye. Mr. Lou Melluzzo, CEO of Air Industries, commented: "This award underscores the significance of our capabilities in providing aftermarket support, and fostering relationships with our valued customers. The considerable momentum that we generated in 2023 is continuing in 2024, and we remain encouraged by the high demand for our products and services. The E-2C/D Hawkeye program represents just one among Air's product lines deployed in mission-critical operations." Deliveries for these landing gear are expected to occur in 2026 through 2027. Air Industries supports the E-2C/D Hawkeye program by providing the main and nose landing gear, as well as the arresting gear. The E-2C/D Hawkeye is a twin-engine, tactical aircraft. Often referred to as the "digital quarterback," it conducts battlefield management and command and control operations for aircraft carrier strike groups.

07:09 EDT Citius' Mino-Lok solution achieves primary and secondary Phase 3 endpoints - Citius Pharmaceuticals announced positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections - CLABSI - or catheter-related bloodstream infections - CRBSI -. The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution. The data demonstrate that Mino-Lok is well-tolerated.

07:07 EDT G2 Goldfields files technical report for updated MRE at OKO Project - G2 Goldfields announced that an independent technical report entitled "NI 43-101 Technical Report and Mineral Resource Estimate for the Oko Gold Property in the Co-operative Republic of Guyana, South America", with an effective date of March 27, 2024, has been filed on SEDAR+. The Technical Report is for the updated mineral resource estimate for the Oko property in Guyana, previously announced by the Company in a news release dated April 3, 2024.

07:07 EDT Lam Research announces 10-for-1 stock split, $10B share repurchase plan - Lam Research announced that its Board of Directors approved a $10B share repurchase authorization and a forward split of its outstanding shares of common stock at a ratio of 10:1."The share repurchase authorization announced today will execute over an indeterminate period of time and is consistent with our plan to return 75% to 100% of free cash flow to stockholders in the form of dividends and share buybacks," said Doug Bettinger, Lam's Executive Vice President, and CFO. "Furthermore, the stock split announced today will enable a larger proportion of Lam's worldwide employee base to participate in the company's employee stock plans." The company is authorized to repurchase up to $10B of common stock. The new share repurchase authorization supplements the remaining balances from any prior authorizations. Repurchases may be made through both public market and private transactions and may include the use of derivative contracts and structured share repurchase agreements. This repurchase program has no termination date and may be suspended or discontinued at any time. The stock split is expected to be effective after market close on Wednesday, October 2, 2024, for stockholders of record at that time. Lam Research's common stock will begin trading on a post-split basis at the market open on Thursday, October 3, 2024, under the company's existing trading symbol "LRCX."

07:06 EDT MasterBrand to acquire Supreme Cabinetry Brands for $520M in cash - MasterBrand has agreed to acquire Supreme Cabinetry Brands from GHK Capital Partners for $520M in cash. Pre-synergies, the purchase price represents a multiple of approximately 8.9x Supreme's adjusted EBITDA for the twelve months ending March 31, inclusive of $25M net present value of cash tax attributes being acquired in the transaction. Including anticipated annual run-rate cost synergies of $28M, the purchase price multiple of adjusted EBITDA is approximately 5.9x. The acquisition is expected to deliver annual run-rate cost synergies of $28M by the end of year three. These will come from areas including procurement, facility optimization, and overhead expenses. In addition to the cost synergies, MasterBrand anticipates commercial synergies across the companies' complementary channels and product lines. The acquisition is expected to be accretive to adjusted diluted EPS within the first full year after closing. The closing of the acquisition is subject to customary closing conditions, including antitrust clearance in the United States, and is expected to be completed during the third quarter of 2024. While MasterBrand intends to fund the transaction through cash on hand and existing credit facilities, the company has also arranged an incremental debt commitment from JPMorgan Chase Bank, N.A. to ensure liquidity to support its ongoing capital allocation priorities. MasterBrand anticipates its pro forma net debt to adjusted EBITDA will be approximately 2.4 - 2.6x as of the expected closing date of the transaction. MasterBrand plans to utilize the strong free cash flow generation of the combined organization to reduce this ratio back to its target range of under 2.0x within two years post-close.

07:05 EDT Monte Rosa Therapeutics presents data at DDW 2024 on MRT-6160 - Monte Rosa Therapeutics announced the company will present preclinical data at Digestive Disease Week, DDW, 2024, being held May 18-21 in Washington, D.C. The data showed that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis. Summary of findings: MRT-6160 was shown to inhibit disease progression, prevent colon inflammation, and reduce pro-inflammatory cytokine production in a murine T-cell transfer model of colitis. MRT-6160-mediated murine (m)VAV1 degradation prevented disease progression by 85% compared to vehicle, and also reduced the disease activity index score compared to a standard of care control. Transcriptional analysis of colon tissue showed reduced expression of inflammatory-disease associated T-cell activation, Th17 differentiation, chemokine, and calprotectin subunit genes. MRT-6160 reduced CD4+ T-cell expression of TNF and IL-17A, demonstrating a highly favorable profile compared to active control of anti-TNF antibodies. Additionally, in vitro treatment of human PBMCs with MRT-6160 led to concentration-dependent degradation of human (h)VAV1 in immune cells and inhibited T-cell receptor-mediated expression of pro-inflammatory cytokines and proliferation.

07:04 EDT Aslan Pharmaceuticals presents data on eblasakimab as ATS conference - ASLAN Pharmaceuticals announced the late-breaking poster presentation of translational data from head-to-head studies of eblasakimab and dupilumab in human healthy and COPD-derived lung tissue models at the American Thoracic Society, ATS, International Conference 2024 in San Diego, California. Eblasakimab Significantly Alleviates IL-4 and IL-13 Induced Bronchial Airway Constriction in COPD-Derived Lung Slices: PCLS from a 66-year-old male with no known history of lung diseases and a 67-year-old female with COPD were used to test constriction and dilation responses to different treatment conditions including IL-4, IL-13, methacholine, formoterol, and a range of concentrations of dupilumab and eblasakimab. In both healthy and COPD-derived lung tissues, eblasakimab significantly reduced IL-4- and IL-13-induced bronchial airway constriction. In IL-4 and IL-13 pre-treated healthy lung tissues, eblasakimab further restored formoterol-induced airway dilation, significantly better than dupilumab at the lower concentration, and improved methacholine-induced constriction. The results suggest eblasakimab may provide a therapeutic benefit in reducing IL-4- and IL-13-induced airway hyperresponsiveness and that eblasakimab may provide relief in situations of acute airway constriction. In COPD PCLS, eblasakimab showed significant improvement across all measured bronchial outcomes whereas dupilumab, tested at the same concentrations, did not achieve statistical significance relative to placebo for all measures. The results support further investigation of eblasakimab as a therapeutic option for COPD with potentially more effective blockade of Type-2 mediated effects in lung tissue and improvement in bronchoconstriction.

07:02 EDT Algernon Pharmaceuticals engages ICP Securities for market making services - Algernon Pharmaceuticalshas engaged the services of ICP Securities to provide automated market making services, including use of its proprietary algorithm, ICP Premium. ICP will receive a fee of CDN $7,500 plus applicable taxes per month, payable monthly in advance. The agreement between the Company and ICP is for an Initial Term of three months and shall be automatically renewed for subsequent one month terms unless either party provides at least thirty days written notice prior to the end of the Initial Term or an Additional Term, as applicable. There are no performance factors contained in the agreement and no stock options or other compensation are being granted in connection with the engagement. ICP and its clients may acquire an interest in the securities of the Company in the future. ICP is an arm's length party to the Company. ICP's market making activity will be primarily to correct temporary imbalances in the supply and demand of the Company's shares. ICP will be responsible for the costs it incurs in buying and selling the Company's shares, and no third party will be providing funds or securities for the market making activities. The Company also announces a grant of 425,000 restricted share units pursuant to its RSU Plan to an employee and a consultant of the Company. Each RSU entitles the recipient to receive one common share of the Company or a cash payment equal to the equivalent of one common share of the Company on vesting. The RSUs vest on the date of grant. The RSUs are subject to approval by regulatory authorities.

06:59 EDT Macy's reports Q1 gross margin 39.2% vs. 40.0% last year - Merchandise margin declined 100 basis points, primarily reflecting additional discounting for slower-moving warm weather products. Delivery expense as a percent of net sales improved 20 basis points from the prior year reflecting ongoing efforts to improve supply chain efficiency.

06:50 EDT Amer Sports sees FY24 gross margin approximately 54% - Sees FY24 operating margin: 10.5%-11.0%.

06:34 EDT Roma Green Finance receives Nasdaq listing deficiency notice - Roma Green Finance received a notice from Nasdaq that Roma is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the company's ordinary shares. The notice indicated that the company has 180 days, or until November 13, 2024, to regain compliance with the Minimum Bid Price Requirement by having the closing bid price of the Ordinary Shares meet or exceed $1.00 per Ordinary Share for at least ten consecutive business days. The Notice has no immediate effect on the listing of the company's Ordinary Shares, which continue to trade on The Nasdaq Capital Market under the symbol "ROMA". The company may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement, including a reverse stock split. If the company does not regain compliance by the compliance deadline, the company may be afforded an additional 180 calendar day period to regain compliance.

06:17 EDT GSK announces SWIFT-1, SWIFT-2 trials on depemokimab met primary endpoints - GSK announced headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count. Both SWIFT-1 and SWIFT-2 met their primary endpoints of a reduction in the annualised rate of clinically significant exacerbations over 52 weeks. Across both trials the overall incidence and severity of treatment-emergent adverse events were similar in patients treated with either depemokimab or placebo. Further analysis of these data is ongoing. Depemokimab is the first ultra-long-acting biologic to be evaluated in phase III trials with a binding affinity and high potency for interleukin-5, enabling six-month dosing intervals for patients with severe asthma. Expertise in respiratory diseases and the science of IL-5 has informed the ongoing evidence generation program evaluating the impact of six-month dosing of sustained IL-5 inhibition in patients achieving clinical remission in severe asthma. The full results of SWIFT-1 and SWIFT-2 will be presented at an upcoming scientific congress and will be used to support regulatory submissions to health authorities worldwide.

06:15 EDT IBM expands watsonx portfolio on AWS - During the annual IBM Think conference, IBM (IBM) announced it is working with Amazon (AMZN) Web Services, or AWS, to make the full portfolio of IBM offerings within the watsonx artificial intelligence, or AI, and data platform available for use with AWS services. The companies plan to integrate IBM watsonx.governance and Amazon SageMaker -- a service to build, train, and deploy machine learning and generative AI models with fully managed infrastructure, tools, and workflows -- to help Amazon SageMaker and watsonx customers manage model risk and support compliance obligations in connection with recent regulatory requirements such as the EU AI Act. This integration rounds out the availability of the watsonx platform in AWS Marketplace, which already includes IBM watsonx.ai and watsonx.data as customer managed offerings. Available in June, watsonx.governance and Amazon SageMaker will help clients streamline workflows, accelerate time to market for AI initiatives, and manage AI across complex IT environments and ecosystems. They will be able to configure and track fully customizable risk assessment and model approval workflows across multiple stakeholders, providing an audit trail in both watsonx and Amazon SageMaker.

06:12 EDT Exact Sciences allowed by court to proceed with lawsuit against Geneoscopy - Exact Sciences announced that a District Court judge denied in part Geneoscopy's motion to dismiss a patent infringement lawsuit filed by Exact Sciences in the U.S. District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy's future infringement and false advertising. Exact Sciences filed the lawsuit in November 2023 to prevent Geneoscopy from infringing upon Exact Sciences' intellectual property central to its Cologuard colorectal cancer screening test and to put an end to Geneoscopy's advertising and promotion about the alleged clinical performance and superiority of ColoSense. Rather than answer for its misconduct, Geneoscopy filed a motion to dismiss the case. On May 15, 2024, Exact Sciences filed a second complaint against Geneoscopy to defend its intellectual property against infringement in Delaware. The case asserts a new patent, the '746 patent, that was issued to Exact Sciences on April 30, 2024. Exact Sciences expects its new case to proceed on a similar schedule as the existing case, given the overlapping issues.

06:06 EDT Sound Group receives Nasdaq notice of non-compliance - Sound Group, formerly known as LIZHI INC., announced that it has received a letter from the NASDAQ Stock Market, dated May 17, notifying the company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2023.

05:55 EDT Volvo unveils production ready autonomous truck Aurora Innovation - Volvo Autonomous Solutions, or V.A.S., unveiled Volvo's (VLVLY) first-ever production ready autonomous truck at the ACT Expo in Las Vegas. The Volvo VNL Autonomous brings together Volvo's commercial vehicle expertise with autonomous driving technology from Aurora Innovation (AUR). The result is an autonomous truck that will be an enabler to increasing freight capacity across the United States.

05:37 EDT Genentech announces FDA granted breakthrough therapy designation for inavolisib - Genentech, a member of Roche, announced that the FDA has granted breakthrough therapy designation for inavolisib, an investigational oral therapy, in combination with palbociclib and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.

05:32 EDT AstraZeneca announces $80B revenue target by 2030 - AstraZeneca revealed its ambition to deliver $80B in total revenue by 2030, up from $45.8B in 2023. The company said this will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade. To drive sustained growth beyond 2030, the company will continue investing in new technologies and platforms. AstraZeneca will maintain its strategic commitment to R&D while focusing on productivity throughout the company, driving operating leverage and enabling the delivery of its ambition for a mid-30s percentage core operating margin by 2026. Beyond 2026, core operating margin will be influenced by portfolio evolution and the company will target at least the mid-30s percentage range. Pascal Soriot, CEO, AstraZeneca said: "Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious $45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for $80 billion by 2030. We are planning to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak year revenues. The breadth of our portfolio together with continued investment in innovation supports sustained growth well past the end of the decade." As AstraZeneca continues to grow across all therapy areas, it will continue to decouple its carbon emissions from its increase in revenue. The company has already reduced its greenhouse gas emissions by 68% from its 2015 baseline while growing total revenue by 85% over the same period. By 2026 the company will be carbon zero for Scope 1 and 2 emissions and by 2030 halve its Scope 3 emissions, on the way to science-based net zero by 2045 at the latest.

05:21 EDT Janus Henderson intends to reject Forseti III offer - Janus Henderson manages funds that own 3,754,750 shares in Karnov Group. The company said, "We consider the SEK 84 per share offer from Forseti III AB to be far below Karnov's intrinsic value and intend to reject the offer. This decision is in line with our value of "Clients Come First - Always" because at Janus Henderson we believe in doing all we can to deliver the best outcomes for our clients and their clients, including zealous advocacy based on rigorous fundamental research in cases such as this."

05:04 EDT Aurora Mobile partners with Moonshot AI Technology - Aurora Mobile announced that it has signed a strategic agreement with Beijing Moonshot AI Technology, an artificial general intelligence company in China, to provide intelligent messaging services and verification services for Moonshot AI's smart assistant app Kimi.